JB Pharma announced strong Q3 FY26 results, with revenue reaching INR 1,065 crores, a 11% year-over-year increase. Domestic formulations grew by 10%, driven by chronic therapies. EBITDA margins improved to 28.7%. The company maintains a top-five position in medicated/herbal lozenges and shows strong performance in acquired portfolios.
Financial Performance
In Q3 FY26, JB Pharma’s revenue reached INR 1,065 crores, representing an 11% YoY growth, with 9M FY26 revenue at INR 3,244 crores, a 9% YoY growth. Domestic formulations revenue was INR 620 crores, up 10% YoY.
Reported EBITDA for Q3 FY26 was INR 296 crores, and operating EBITDA reached INR 305 crores with margins at 28.7%. For 9M FY26, reported EBITDA was INR 906 crores and operating EBITDA reached INR 955 crores, with margins at 29.4%.
Domestic Business
The domestic business sustained momentum, with 10% YoY growth contributing INR 620 crores in Q3 FY26. JB Pharma outperformed the Indian Pharmaceutical Market (IPM) growth, with key brands like Cilacar and Sporlac showing strong performance. Razel franchise recorded YoY growth of 11%, reaching INR 108 crores.
International Business
International business grew by 12% to INR 445 crores in Q3 FY26. International formulations grew by 20% to INR 306 crores, supported by strong exports and branded markets. CDMO business revenue was approximately flat at INR 117 crores.
Key Brands Performance
JB Pharma has five brands in the top 300 in India. Key brands continue to show strong growth including:
Cilacar with Q3 FY26 revenue of INR 908 crs.
Rantac with Q3 FY26 revenue of INR 410 crs.
Metrogyl with Q3 FY26 revenue of INR 327 crs.
Acquired portfolios also performed well, with Sporlac franchise revenue reaching INR 160 crores and Azmarda clocking sales of INR 79 crores.
Source: BSE
